Skip to McMaster Navigation Skip to Site Navigation Skip to main content

Prestigious journal Nature ranks McMaster among the top organizations worldwide for infectious disease research

The rankings are based on a five-year survey of infectious disease-related articles published in the world’s highest-impact scientific journals.

By Blake Dillon October 8, 2026

Two scientists examining cell cultures in a lab.
Matthew Miller, director of McMaster’s Michael G. DeGroote Institute for Infectious Disease Research, with PhD student Emma Palladino.

Experts Featured In This Story

Eric Brown
Eric Brown

Professor

See Profile
Lindsay Kalan
Lindsay Kalan

Associate Professor

See Profile
Matthew S Miller
Matthew S Miller

Professor

See Profile
Fiona Smaill
Fiona Smaill

Professor Emeritus

See Profile
Jonathan Stokes
Jonathan Stokes

Assistant Professor

See Profile
Gerard Wright
Gerard Wright

Scientific Director

See Profile

As the world grapples with a rise in drug-resistant bacteria and emerging viral threats, McMaster University has earned global recognition for its role on the frontlines of both fights: placement among the top 100 organizations worldwide for infectious disease research.

The new infectious disease index, issued today by the prestigious journal Nature, ranks McMaster 79th in the field worldwide — and 4th in Canada — for its leadership in the areas of antimicrobial resistance, drug discovery, diagnostics, virology, vaccinology, and host-pathogen interactions.

The rankings, which are based directly on a five-year survey of infectious disease-related articles published in the world’s highest-impact scientific journals, cement McMaster’s growing reputation as a hub for the critical science shaping how the world detects, treats, and prevents infectious disease.

Matthew Miller, scientific director of the Michael G. DeGroote Institute for Infectious Disease Research (IIDR) at McMaster, says that the new recognition is a testament to the people who have helped establish and maintain a culture of excellence at the university.

“We have done a really excellent job over the course of the last couple of decades ensuring that we recruit the very best researchers in the world within the field of infectious disease research,” says Miller, who is also executive director of McMaster’s health innovation accelerator, NexusHealth. “Those researchers have then gone on to recruit the very best trainees in the world. Students and postdoctoral fellows from all over come to McMaster because they know that this is a really excellent place to make an impact on the field.”

While Miller says every IIDR member has played a key role in the institute’s rise, he is quick to single out the “visionary leadership” of Professor Gerry Wright, who founded the IIDR nearly 20 years ago and served as its director for its first 15 years. Miller says that Wright, now a globally recognized leader in antibiotic discovery and antimicrobial resistance, established a culture of impactful interdisciplinary collaboration from the Institute’s very beginning.

For Wright, those early days are best described as a “lightning-in-a-bottle opportunity” — a moment in time when both McMaster leadership and the Institute’s namesake, Michael DeGroote, were willing to bet on an unconventional approach to infectious disease research.

“The secret sauce to the IIDR is its multidisciplinarity,” Wright says. “It includes biochemical researchers, like me, but also mathematicians who do populations-scale modeling, clinicians who see patients, and chemists who make molecules. The Institute was consciously established to break barriers between disciplines so that we could advance infectious disease research by learning from each other.”

“In the early days, we knew where we were going,” adds Eric Brown, a professor of Biochemistry and Biomedical Sciences and one of the IIDR’s first members. “We set our compass for an ambitious journey, and we set a standard for ourselves, for our trainees, and for our staff.”

Decades later, Brown says that journey is looking more and more like a destination, though he notes those early ambitions for more still endure today. The small team that he and Wright helped establish has since grown into a full-fledged research enterprise with more than 50 dedicated infectious disease experts and hundreds of specialized trainees and staff, all working together across diverse areas of infectious disease research.

Over the past five years alone, this group has collectively made numerous landmark breakthroughs in infectious disease, including the discovery of an entirely novel class of antibiotics, along with new antifungals, adjuvants, and antimalarials; the development of an inhaled COVID-19 vaccine; successful applications of AI to drug discovery; the discovery of new antibiotic-producing gene clusters; and new insights into past pandemics, like the Black Death, drawn from ancient DNA.

Much of this work has been enabled by the IIDR’s core infrastructure, including the Centre for Microbial Chemical Biology, the David Braley Centre for Antibiotic Discovery, and McMaster’s Containment Level 3 laboratory. These state-of-the-art facilities give McMaster researchers open access to the equipment and expertise needed for high-impact science.

“We have a really full-service research ecosystem that allows researchers to get in from the basic level all the way through to translation,” says Lindsay Kalan, the IIDR’s associate director. “This core infrastructure is completely unique to an academic setting. It allows investigators to come in, learn skills, and access equipment that’s often only accessible at large pharmaceutical companies or in industry.”

The IIDR’s infrastructure is being increasingly leveraged for translating discoveries into tangible health solutions. In fact, in partnership with NexusHealth, a team of IIDR researchers has recently advanced its aforementioned inhaled vaccine platform to Phase 2 human trials.

“What I appreciate about McMaster has been the opportunity to step from bench to bedside,” says IIDR member Fiona Smaill, who is co-leading the ongoing clinical trials. “People talk about bench to bedside, but we actually do bench to bedside. This has allowed us to establish a generation of research scientists who can see that that their work has clinical impact.”

For IIDR member Jon Stokes, who blends computational and wet lab approaches to drug discovery, McMaster’s success in infectious disease research stems from the Institute’s right-sizedness.

“Institutes can get so big where you don’t know anybody and you feel siloed, even though that vast collection of people has every type of expertise you could hope for,” he says. “At the other end, you can have an institute that’s too small, where you do know everybody, but the diversity of expertise is insufficient to solve complex, multi-property problems like those in infectious disease. The IIDR is right in the Goldilocks zone.”

Talented people. A culture of crossing disciplines. A shared ambition. Critical infrastructure. Translational research. And a scale for impact. Every IIDR member seemingly has a different answer for why McMaster has landed among the world’s top institutions for infectious disease research — a testament, Wright says, to the many strengths of the Institute.

“You’re not going to find a place that’s better equipped, that has more collaborative individuals, or people who are more interested in moving the needle in infectious disease research anywhere in the world,” Wright says. “The IIDR is an absolute gem, and I couldn’t be more proud to be a member of it.”

A smiling older adult leans out to look out of a window.

Analysis: Older adults aging where they choose: Possibility or illusion?

It's not enough to ask older adults where they want to live — aging in place requires community and government support for changing needs, write Brenda Vrkljan and Evelyne Durocher.
A smiling Manali Mukherjee in a lab.

Immunologist Manali Mukherjee receives Falling Walls Women’s Impact Award 

The prestigious international award recognizes Mukherjee’s patient-centred, evidence-based research on Long COVID. 
Two researchers in lab coats and gloves smile as they work on complicated apparatus in the lab with lots of pipes and tubes.

Inside the McMaster lab that is making life-saving medicine more affordable

German life sciences company Sartorius and McMaster are working together to make it cheaper and more efficient to manufacture medications and drive down patient costs.